Literature DB >> 25131257

Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator.

Runglawan Silakit1, Watcharin Loilome, Puangrat Yongvanit, Porncheera Chusorn, Anchalee Techasen, Thidarut Boonmars, Narong Khuntikeo, Nittaya Chamadol, Chawalit Pairojkul, Nisana Namwat.   

Abstract

BACKGROUND: This study aimed to investigate the miR-192 levels in patients' sera of liver fluke-associated cholangiocarcinoma (CCA) for a prospective prognostic indicator.
METHODS: MicroRNA polymerase chain reaction (PCR) array was performed using pooled serum samples from 11 CCA patients and nine healthy subjects. Selected miRNAs were verified for the differential levels in both sera and tumor tissues (of patients and Opisthorchis viverrini (Ov)-induced CCA model) using TaqMan miRNA expression assay.
RESULTS: Our results demonstrated that miR-192 was significantly higher in the serum of CCA patients than that in healthy subjects giving a sensitivity of 74% and specificity of 72% (area under the curve [AUC] = 0.803; 95% confidence interval [CI], 0.708-0.897, P < 0.0001). Serum miR-192 examined in Ov infected subjects and subjects with periductal fibrosis were increased but not statistically significantly when compared with healthy subjects. High levels of serum miR-192 were significantly correlated with lymph node metastasis (P = 0.047) and shorter survival compared with individuals with low levels of serum miR-192 (hazard ratio [HR] 2.076, 95% CI 1.004-4.291, P = 0.049). We also found that the expression levels of miR-192 appeared to be elevated in both CCA tissues of patients and in Ov-induced CCA tissues of a hamster model.
CONCLUSIONS: This finding indicates that elevated levels of miR-192 may be involved in CCA genesis and have a potential utility as a noninvasive prognostic indicator for CCA patients.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Cholangiocarcinoma; Opisthorchis viverrini; Prognostic indicator; Serum miR-192

Mesh:

Substances:

Year:  2014        PMID: 25131257     DOI: 10.1002/jhbp.145

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  27 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  The role of miRNAs in cholangiocarcinoma.

Authors:  Jessica A Howell; Shahid A Khan
Journal:  Hepat Oncol       Date:  2016-03-29

Review 3.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

Review 4.  Circulatory microRNAs: promising non-invasive prognostic and diagnostic biomarkers for parasitic infections.

Authors:  Hossein Ghalehnoei; Abouzar Bagheri; Mahdi Fakhar; Mohammad Amir Mishan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-15       Impact factor: 3.267

5.  Role of microRNAs in host defense against Echinococcus granulosus infection: a preliminary assessment.

Authors:  Mara Mariconti; Ambra Vola; Tommaso Manciulli; Francesca Genco; Raffaella Lissandrin; Valeria Meroni; Mara Rosenzvit; Francesca Tamarozzi; Enrico Brunetti
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

6.  Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.

Authors:  Xiongbo Wu; Min Xia; Dayang Chen; Fang Wu; Zhifa Lv; Qiang Zhan; Yang Jiao; Wenjie Wang; Guangxia Chen; Fangmei An
Journal:  Tumour Biol       Date:  2016-09-22

7.  Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.

Authors:  Gyem Tshering; Palden Wangyel Dorji; Wanna Chaijaroenkul; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

8.  MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.

Authors:  Li-Juan Wang; Chen-Chen He; Xin Sui; Meng-Jiao Cai; Cong-Ya Zhou; Jin-Lu Ma; Lei Wu; Hao Wang; Su-Xia Han; Qing Zhu
Journal:  Oncotarget       Date:  2015-03-20

Review 9.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 10.  Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.

Authors:  Pablo Letelier; Ismael Riquelme; Alfonso H Hernández; Neftalí Guzmán; Jorge G Farías; Juan Carlos Roa
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.